2025
A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease
Shenoy S, Kanter J, Kassim A, Fitzhugh C, Stenger E, Bhatia M, Pecker L, Krishnamurti L, King A. A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease. Blood Advances 2025, 9: 3090-3103. PMID: 39993235, DOI: 10.1182/bloodadvances.2024013953.Peer-Reviewed Original Research30 year trends in racial disparities for early stage lung cancer treatment.
Lynch O, Lee D, Soulos P, Yu J, Herrin J, Gross C. 30 year trends in racial disparities for early stage lung cancer treatment. Journal Of Clinical Oncology 2025, 43: 1599-1599. DOI: 10.1200/jco.2025.43.16_suppl.1599.Peer-Reviewed Original ResearchReceipt of curative therapyReceipt of curative treatmentCurative therapyCurative treatmentLung cancer treatmentWhite patientsBlack patientsReceipt of treatmentRacial disparitiesBlack-white differencesStage I-II NSCLCEarly stage lung cancerCancer treatmentStage lung cancerYears prior to diagnosisMedicare beneficiariesMonths of diagnosisRetrospective cohort studyMultivariate logistic regressionAssessed temporal trendsNon-LatinxProbability of treatmentPredictive probability of treatmentSEER-MedicareLung cancerHow I treat challenging transfusion cases in sickle cell disease
Chou S, Hendrickson J. How I treat challenging transfusion cases in sickle cell disease. Blood 2025, 145: 2257-2265. PMID: 38728382, DOI: 10.1182/blood.2023023648.Peer-Reviewed Original ResearchDelayed Hemolytic Transfusion ReactionSickle cell diseaseRed blood cellsTransfusion of red blood cellsRed blood cell alloantibodiesRed blood cell transfusionCell diseaseHemolytic transfusion reactionsManagement of complicationsAlloimmunized patientsRh alloimmunizationCurative therapyTransfusion guidelinesTransfusion recipientsClinical dilemmaFuture transfusionsTransfusionPatient populationTransfusion casesTransfusion reactionsBlood donorsRH variantsBlood cellsAlloimmunizationMedicine providerseNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis.
Casanova N, Herazo-Maya J, Kempf C, Sun B, Song J, Hernandez A, Canizales Galaviz J, Sun X, Camp S, Ledford J, Hellinger R, Rodriguez M, Zhao A, Unterman A, Rosas I, Duncan S, Thannickal V, Hufford M, Ahmed M, Zaghloul N, Gupta A, Bime C, Sammani S, Stansfield B, Chen J, Anandhan A, Disney M, Ooi A, Kee S, Karampitsakos T, Benos P, Kaminski N, Zhang D, Garcia J. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2025 PMID: 40126452, DOI: 10.1165/rcmb.2024-0342oc.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisExtracellular nicotinamide phosphoribosyltransferaseDamage-associated molecular pattern proteinToll-like receptor 4Lung tissuePulmonary fibrosisBleomycin-induced lung fibrosis modelNASH-associated hepatic fibrosisIdiopathic pulmonary fibrosis subjectsRadiation-induced lung fibrosisIdiopathic pulmonary fibrosis patientsBleomycin-exposed miceIdentification of novel therapeuticsLung fibrosis modelMurine lung tissueMurine pulmonary fibrosisLung fibrosis developmentCurative therapyGene expressionC57BL6 miceLung fibrosisIPF treatmentFatal disorderHuman PBMCsFibrosis developmentAdvancing drug development in myelodysplastic syndromes
Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationEnd pointsStem cell malignanciesTime-to-event end pointsStem cell transplantationUS Food and Drug AdministrationTreatment of patientsFood and Drug AdministrationClinical trial designDrug developmentMyelodysplastic syndromeCell transplantationCurative therapyRisk stratificationPoor prognosisCell malignancyTransformative therapiesDrug AdministrationBiomarker developmentResponse definitionsTrial designFunctional assessmentTherapyPatients
2024
From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner V, Safi A, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases. Frontiers In Immunology 2024, 15: 1276306. PMID: 38715609, PMCID: PMC11074450, DOI: 10.3389/fimmu.2024.1276306.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHead and neck cancerBreast cancerMonoclonal antibodiesCheckpoint inhibitorsSkin cancerReconstructive surgeryNon-surgical treatment strategiesProlonged progression-free survivalSuboptimal treatment plansProgression-free survivalNon-surgical therapySurgical tumor resectionImpaired patient outcomeStandardized treatment algorithmSurgical therapy planningAnti-cancer strategyUnresectable tumorsConventional chemotherapyRemission rateTumor resectionCurative therapyTargeted therapyNeck cancerOncology cases131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Foran J, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Nagl N, Brodin P, Vusirikala M, Nahar A, Sandmaier B, Pagel J, Giralt S, Desai A, Seropian S. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes. Transplantation And Cellular Therapy 2024, 30: s110-s111. DOI: 10.1016/j.jtct.2023.12.174.Peer-Reviewed Original ResearchHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationTP53 mutationsMedian OSOverall survivalPositive PTCell transplantationCC groupDays post-hematopoietic cell transplantationControlled phase 3 studiesEradication of leukemic cellsPost-hematopoietic cell transplantationImprove outcomesConventional careMedian overall survivalTotal body irradiationPhase 3 studyOutcomes of PTPost Hoc AnalysisR/R AMLBody irradiationAML patientsPrimary endpointCurative therapyRelapse ratePulmonary complications of advanced chronic liver diseases: an updated review
Thevenot T, Raevens S, Aujayeb A, Banini B, Cadranel J, DuBrock H. Pulmonary complications of advanced chronic liver diseases: an updated review. Exploration Of Digestive Diseases 2024, 3: 301-325. DOI: 10.37349/edd.2024.00053.Peer-Reviewed Original ResearchPulmonary complicationsHepatopulmonary syndromeLiver transplantationHepatic hydrothoraxAdvanced chronic liver diseasePre-existing lung diseasePathophysiology of HHLack of routine screeningChronic liver diseaseLiver transplant survivalMultidisciplinary team approachPortopulmonary hypertensionCirrhotic populationCurative therapyPortal hypertensionIncreasing dyspneaTherapeutic optionsClinical featuresMELD exception pointsAwaiting transplantationLung diseasePatient populationLiver diseaseComplicationsTransplant survival
2023
Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2022
Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials
Krishnamurti L, Neuberg D, Sullivan K, Smith S, Eapen M, Walters M. Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials. Transplantation And Cellular Therapy 2022, 29: 217-221. PMID: 36270432, PMCID: PMC10539686, DOI: 10.1016/j.jtct.2022.10.008.Peer-Reviewed Original ResearchConceptsBone marrow transplantationSickle cell diseaseMarrow transplantationNonmalignant diseasesCell diseaseAdult sickle cell diseaseMyeloablative bone marrow transplantationSingle-arm feasibility studyYoung adultsCellular therapy trialsMulticenter National InstituteRegimen-related toxicitySingle-arm studyFrequency of HLACoronavirus disease 2019 (COVID-19) pandemicAcademic medical centerDisease 2019 pandemicShort-term endpointsBMT centersBMT regimenCare armPain episodesPrimary endpointStandard careCurative therapyImaging biomarkers for diagnosis and treatment response in patients with lymphedema
Maita K, Garcia JP, Torres RA, Avila FR, Kaplan JL, Lu X, Manrique OJ, Ciudad P, Forte AJ. Imaging biomarkers for diagnosis and treatment response in patients with lymphedema. Biomarkers In Medicine 2022, 16: 303-316. PMID: 35176878, DOI: 10.2217/bmm-2021-0487.Peer-Reviewed Original Research
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb AManagement of the Older Patient with Myelodysplastic Syndrome
Shallis RM, Zeidan AM. Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging 2021, 38: 751-767. PMID: 34342860, DOI: 10.1007/s40266-021-00881-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeOlder patientsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationPrevalence of frailtyMajority of patientsStem cell transplantationPatient-specific factorsDrug-drug interactionsQuality of lifeAbsolute contraindicationPalliative therapyCare therapyCurative therapyIntensive therapyCell transplantationOptimal treatmentSubgroup analysisPatientsPsychosocial issuesSyndromeTherapyPersonalized treatmentAge associatesOlder populationFactors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease
Kanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAdvanced liver diseaseLiver diseaseLiver transplantationCohort studyMedical recordsOrgan transplantsVeterans Affairs Health Care SystemLower ratesRetrospective cohort studyWait-listed patientsAfrican American patientsComprehensive electronic medical recordsElectronic medical recordsHealth care systemReferral stepsLiver allograftsLiver transplantAdult patientsAlcohol etiologyLow annual incomePatient ageCurative therapyLiver cirrhosisSodium score
2020
Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. Transplantation And Cellular Therapy 2020, 26: s32-s33. DOI: 10.1016/j.bbmt.2019.12.575.Peer-Reviewed Original ResearchHematopoietic cell transplantationSalvage therapyOlder patientsCC armConventional careCC patientsConventional hematopoietic cell transplantationGrade 3 febrile neutropeniaAllogeneic hematopoietic cell transplantationPre-treated patientsPhase 3 trialFailure of chemotherapyYears of ageFebrile neutropeniaInduction therapyActive diseaseMyeloablative conditioningRefractory AMLBackground PatientsBM blastsInfusion reactionsMethods PatientsTransplant candidatesAllogeneic transplantationCurative therapy
2019
A Novel Small Molecule Inhibits Intrahepatocellular Accumulation of Z-Variant Alpha 1-Antitrypsin In Vitro and In Vivo
Zhang X, Pham K, Li D, Schutte RJ, Gonzalo DH, Zhang P, Oshins R, Tan W, Brantly M, Liu C, Ostrov DA. A Novel Small Molecule Inhibits Intrahepatocellular Accumulation of Z-Variant Alpha 1-Antitrypsin In Vitro and In Vivo. Cells 2019, 8: 1586. PMID: 31817705, PMCID: PMC6953066, DOI: 10.3390/cells8121586.Peer-Reviewed Original ResearchConceptsLiver diseaseAssociated liver injuryChronic liver diseaseMutant alpha 1Common genetic causePiZ miceCurative therapyLiver injuryLiver fibrosisNovel small moleculesAnimal modelsAlpha 1Genetic causeDiseaseIntracellular accumulationAlphaCandidate compoundsHuman alphaMutant alphaCell modelAATDFibrosisInjuryTherapySmall moleculesCurative Therapies for Sickle Cell Disease.
Khemani K, Katoch D, Krishnamurti L. Curative Therapies for Sickle Cell Disease. Ochsner Journal 2019, 19: 131-137. PMID: 31258425, PMCID: PMC6584191, DOI: 10.31486/toj.18.0044.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseHaploidentical donorsSibling donorsCurative therapyUnrelated donorsCell diseaseHLA-identical sibling donorsRelated haploidentical donorsEvent-free survivalIdentical sibling donorsBone marrow transplantationStem cell transplantationAmelioration of symptomsHuman leukocyte antigenComparative clinical trialsGene therapyUse of HLAStable long-term engraftmentLong-term engraftmentMarrow transplantationRelated donorsSevere morbidityCurative treatmentOrgan damageEpidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advancesNoninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation
Korutla L, Rickels MR, Hu RW, Freas A, Reddy S, Habertheuer A, Harmon J, Korutla V, Ram C, Naji A, Vallabhajosyula P. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation. American Journal Of Transplantation 2019, 19: 1852-1858. PMID: 30801971, PMCID: PMC7043773, DOI: 10.1111/ajt.15322.Peer-Reviewed Original ResearchConceptsIslet cell transplantationAutoimmune type 1 diabetesType 1 diabetesCell transplantationT1D autoimmunityNoninvasive diagnosisPancreatic β-cell injuryGlutamic acid decarboxylase 65Time-matched analysisΒ-cell injuryTransplanted β-cellsHyperglycemia onsetIslet injuryRecurrent autoimmunityHypoglycemic unawarenessTime-specific increaseIslet autoantigensCurative therapyT1D patientsImmunologic rejectionExogenous insulinInjury typeControl subjectsIslet transplantationDonor islets
2018
Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma
Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal Of Hepatology 2018, 70: 700-709. PMID: 30553841, PMCID: PMC10878126, DOI: 10.1016/j.jhep.2018.12.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct NeoplasmsCancer-Associated FibroblastsCell Line, TumorCholangiocarcinomaDisease Models, AnimalEndothelial CellsHeterograftsHumansImatinib MesylateLiverLymphangiogenesisLymphokinesMaleMiceMice, SCIDMyofibroblastsPlatelet-Derived Growth FactorProtein Kinase InhibitorsRatsRats, Inbred F344Receptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CConceptsCancer-associated fibroblastsLymphatic endothelial cellsCholangiocarcinoma specimensMetastatic spreadStromal reactionLiver myofibroblastsGrowth factorExtensive stromal reactionLymph node metastasisEarly metastatic spreadLevels of VEGFBH3 mimetic navitoclaxPlatelet-derived growth factorRole of PDGFVascular growth factorsTumor-associated lymphangiogenesisVEGF-C secretionTransendothelial electric resistanceCholangiocarcinoma invasivenessHuman lymphatic endothelial cellsCurative therapyNode metastasisBiliary treeEarly metastasisPDGFRβ inhibitor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply